Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02336087|
Recruitment Status : Active, not recruiting
First Posted : January 12, 2015
Last Update Posted : March 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Adenocarcinoma Unresectable Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7||Drug: Gemcitabine Hydrochloride Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation Drug: Metformin Hydrochloride Dietary Supplement: Therapeutic Dietary Intervention Other: Laboratory Biomarker Analysis Other: Quality-of-Life Assessment||Phase 1|
I. To assess the compliance, toxicity and feasibility of administering gemcitabine hydrochloride (gemcitabine), nab-paclitaxel (abraxane), metformin hydrochloride (metformin), and the dietary supplement (DS).
I. To assess the response rate associated with this combination therapy in pancreatic cancer patients.
II. To assess the progression-free survival and overall survival of all patients who start protocol therapy, and describe the outcomes based on measures of compliance during the lead-in week, and compliance with supplement during chemotherapy.
III. To collect and analyze peripheral blood and pre-treatment biopsy samples for an exploratory analysis of biological correlatives.
IV. To assess quality of life utilizing the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire.
Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) on days 1, 8, and 15. Patients also receive metformin hydrochloride orally (PO) twice daily (BID) starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer|
|Actual Study Start Date :||January 14, 2016|
|Actual Primary Completion Date :||October 4, 2020|
|Estimated Study Completion Date :||December 31, 2023|
Experimental: Treatment (gemcitabine, Abraxane, metformin, DS)
Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Gemcitabine Hydrochloride
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Drug: Metformin Hydrochloride
Dietary Supplement: Therapeutic Dietary Intervention
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other Name: Quality of Life Assessment
- Feasibility of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement [ Time Frame: Up to 24 months ]Feasibility is defined at 1 or fewer patients experiencing a dose limiting toxicity within the first 6 patients.
- Compliance of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (percent of patients who are fully compliant) [ Time Frame: Up to 24 months ]The percent of patients who are fully compliant in the first week will be estimated with a 95% confidence interval. The compliance will be measured similarly for each course prior to study treatment discontinuation. The impact of less than full compliance (both during the lead-in period and during chemotherapy) on the biomarkers and outcome, and qualitatively study patient reasons and specific supplement patterns related to non-compliance will be explored.
- Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4) [ Time Frame: Up to 24 months ]Summarized using the National Cancer Institute Common Terminology for Adverse Events criteria version 4. Tables will summarize the highest grade per patient that is possibly related to treatment, and the number of patients requiring dose modifications will also be presented.
- Progression-free survival [ Time Frame: Up to 24 months ]Evaluated using the Kaplan-Meier methods.
- Overall survival [ Time Frame: Up to 24 months ]Evaluated using the Kaplan-Meier methods.
- Time to treatment failure [ Time Frame: Up to 24 months ]Evaluated using the Kaplan-Meier methods.
- Analysis of biological correlates (Peripheral blood will be evaluated) [ Time Frame: Up to 24 months ]Peripheral blood will be evaluated. Standard descriptive methods will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment) in order to examine whether observed patterns are consistent with hypothesized patterns.
- Quality of life, assessed using the FACT-G questionnaire [ Time Frame: Up to 24 months ]Standard descriptive methods will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment) in order to examine whether observed patterns are consistent with hypothesized patterns.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients must have a histologic diagnosis of pancreatic adenocarcinoma
- Patient must have unresectable disease
- Patients must not have received prior chemotherapy except for the following circumstances; gemcitabine and capecitabine chemotherapy given in the adjuvant setting is allowed if the recurrence is greater than 6 months from the completion of chemotherapy; radiation sensitizing doses of 5-fluororuracil or capecitabine are allowed as part of adjuvant treatment and recurrence must be documented greater than 6 months from the completion of adjuvant therapy
- Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Absolute neutrophil count > 1,500/mcl
- Platelet count > 100,000/mcl
- Creatinine < 1.4 mg/dl and/or a measured creatinine clearance > 60 cc/min
- Bilirubin < 1.4 mg/dl
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 3.0 times the upper limit of normal
- Patients currently being treated for severe infections or who are recovering from major surgery or other intercurrent illnesses are ineligible until recovery is deemed complete by the investigator
- Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- Patients must be able to swallow pills and must not have malabsorption problems or ongoing nausea and vomiting that would affect oral treatment
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
- Patients currently taking metformin will be eligible
- Patients allergic to eggs are not eligible
- Patients taking additional dietary/herbal supplements (excluding Senekot) outside of this protocol and refusing to stop are not eligible
- Patients requiring warfarin are not eligible
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336087
|United States, California|
|City of Hope Medical Center|
|Duarte, California, United States, 91010|
|City of Hope Rancho Cucamonga|
|Rancho Cucamonga, California, United States, 91730|
|City of Hope South Pasadena|
|South Pasadena, California, United States, 91030|
|City of Hope West Covina|
|West Covina, California, United States, 91790|
|Principal Investigator:||Vincent Chung||City of Hope Medical Center|
|Responsible Party:||City of Hope Medical Center|
|Other Study ID Numbers:||
NCI-2014-02612 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
14122 ( Other Identifier: City of Hope Medical Center )
|First Posted:||January 12, 2015 Key Record Dates|
|Last Update Posted:||March 21, 2023|
|Last Verified:||March 2022|
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs